EUCTR2022-000336-28-DK招募中1 期
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 138
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. The subject (or, when applicable, the subject’s legally acceptable representative) signs an informed (e)consent form indicating that the subject has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts. (additionally for subjects in Germany or Austria: the subject has been informed of the nature, significance, and
- •implications of the clinical study and is willing and able to understand and fully comply with study procedures and requirements (including
- •digital tools and applications) in the opinion of the investigator. If the subject becomes incompetent over the course of the study, a legally
- •authorized court-appointed representative or an appointed agent in health matters (ie, legally acceptable representative) will need to be
- •identified and the subject will need to provide assent, in accordance with the local regulations, guidelines, and the IRB/IEC to provide informed
- •consent on the subject's behalf to continue in the clinical study).
- •2. The subject is an outpatient of either sex, at least 40 years old, at the time of consent.
- •3. Subjects must, in the opinion of the investigator, be able to participate in all scheduled evaluations, likely to be compliant, and likely to complete all required tests, including neuroimaging brain scans and lumbar punctures.
- •4. The subject has a body mass index =18 and =35 kg/m2 at screening.
- •5. The subject has a diagnosis of possible or probable MSA using the modified Gilman et al, 2008 diagnostic criteria.
- •6. The subject’s onset of first MSA symptoms (including parkinsonism, cerebellar symptoms, orthostatic or urinary symptoms) occurred =4 years before screening as assessed by the investigator..
- •7. The subject’s anticipated life expectancy is =3 years, per investigator judgment.
- •8. The subject has an UMSARS Part I score of =21, and additionally has:
- •a) Severity score =2 on the swallowing item (#2) at screening visit
- •(Visit 1).
- •b) Severity score =2 on the ambulation item (#7) at screening visit
- •(Visit 1).
- •c) Severity score =2 on the falling item (#8) at screening visit
- •(Visit 1).
- •9. The subject has an UMSARS Part IV disability score =3 at screening visit
- •(Visit 1).
- •10. Subject has a MoCA =18. Additionally, subject has sufficiently intact cognition to complete study and follow study instructions, per investigator´s judgment.
- •11. A male subject who is nonsterilized (fertile) and sexually active with a female partner of childbearing potential is eligible to participate if he agrees to use a barrier method of contraception (ie, condom with or without spermicide) from the signing of informed (e)consent throughout the study and for 90 days plus 5 half-lives (total of 190 days) after the last dose. In addition, they must be advised not to donate sperm during
- •this period. The female partner of a male subject should also be advised to use a highly effective method of contraception.
- •12. Female subjects are eligible to participate if (a) they are not pregnant or nursing and (b) they are of nonchildbearing potential or agree to use highly effective contraception from the signing of informed consent throughout the study and for 30 days plus 5 half-lives (total of 130 days) after the last dose of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 76
排除标准
- •1. The subject has serious or unstable clinically significant illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic or autoimmune (eg, multiple sclerosis), hematologic, or other major disease, which, in the judgment of the investigator, is poorly controlled or otherwise likely to deteriorate, compromises the subject’s safety or ability to complete the study, or compromises the interpretation of the study results.
- •2. The subject has medical problems (neurological, visual, orthopedic, psychiatric) that may significantly interfere with completion of the study or interpretation of study endpoints or may confound diagnosis.
- •3. The subject has a disorder that is likely to interfere with drug disposition and elimination.
- •4. In the opinion of the investigator, the subject has a diagnosis of depression or other psychiatric disorder, as defined by DSM-5, AND this disorder is poorly controlled and of sufficient severity to interfere with completion of the study or interpretation of the endpoints.
- •5. The subject is considered by the investigator to be a imminent risk of suicide or injury to self, others, or property, or the subject has attempted suicide within the past year before screening.
- •6. The subject has a history of alcohol or substance use disorder (except tobacco use disorder), as defined by the DSM-5, within 1 year before screening or between screening and randomization
- •7. The subject has positive finding on an alcohol or illicit drug screen.
- •8. The subject has undergone surgery for the treatment of MSA (eg, pallidotomy, deep brain stimulation, fetal tissue transplantation).
- •9. History of epilepsy or seizures, except self-limited febrile childhood seizures.
- •10. Contraindication to lumbar puncture (as assessed by the Investigator). A subject whose CSF cannot be collected will be excluded.
- •11. The subject has hypersensitivity to TAK-341 or any excipients used in its formulation.
- •12. Subject has a history of cancer in the past 5 years (does not apply to participants with carcinoma in situ that has been resolved without
- •further treatment, or basal cell carcinoma; these subjects may be included after approval by the sponsor or designee).
- •13. Clinically significant abnormality at screening or between screening and randomization in physical examination findings, vital signs, electrocardiograms (ECGs), or clinical laboratory test results
- •14.Presence of any of contraindications to MRI as assessed by the Investigator.
- •15. Ophthalmic abnormalities
- •16. At the screening visit: estimated glomerular filtration rate (determined with the Chronic Kidney Disease Epidemiology Collaboration equation) <50 mL/min; QT interval with Fridericia correction method >450 ms for male subjects and >470 ms for female subjects; a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >1.5 × the upper limit of normal.
- •17. Clinically significant vital sign abnormalities at screening or Visit 2 (Day 1), defined as (a) systolic blood pressure =160 mm Hg, (b) diastolic blood pressure =90 mm Hg (blood pressure assessed with the subject at rest in the seated position; may be repeated up to 3 times), or (c) pulse rate <45 or >100 beats per minute (subject at rest in the seated position; may be repeated up to 3 times).
- •18. Positive hepatitis B surface antigen test result, known or suspected active hepatitis C infection, or known history of HIV infection.
- •19. Brain MRI showing clinically
研究者
相似试验
进行中（未招募）
1 期
An experimental study in men and women with head and neck cancer to test the safety, tolerability and the effects of addition of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activate part of the immune systemEUCTR2018-000789-13-BEISA Therapeutics B.V.194
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First RelapseFirst relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignanciesMedDRA version: 9.1 Level: LLT Classification code 10033160 Term: Ovarian epithelial cancer recurrentEUCTR2008-005872-29-FREisai Limited
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First RelapseFirst relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignanciesMedDRA version: 9.1Level: LLTClassification code 10033160Term: Ovarian epithelial cancer recurrentEUCTR2008-005872-29-PTEisai Limited900
进行中（未招募）
不适用
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First RelapseFirst relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignanciesMedDRA version: 14.0Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005872-29-NLEisai Limited1,080
进行中（未招募）
1 期
An experimental study in men and women with head and neck cancer to test the safety, tolerability and the effects of addition of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activate part of the immune systemHPV16-Positive Oropharyngeal Cancer (OPC)MedDRA version: 21.0Level: PTClassification code 10031098Term: Oropharyngeal cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000789-13-CZISA Therapeutics B.V.194